Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    22955616 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
Conditions: Luminal A Breast Cancer;   Luminal B Breast Cancer;   CPS-EG Score;   Postneoadjuvant Treatment With CDK 4/6 Inhibitor;   Hormonreceptor Positive
Interventions: Drug: Palbociclib PD-0332991;   Behavioral: Patient reported outcomes;   Drug: Placebo

Indicates status has not been verified in more than two years